Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB3 | P05106 | 1/20 | 0.65 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.65 |
| ▸ | ACE | P12821 | 1/20 | 0.59 |
| ▸ | PTPN1 | P18031 | 3/20 | 0.56 |
| ▸ | PPARA | Q07869 | 7/20 | 0.55 |
| ▸ | PPARG | P37231 | 6/20 | 0.55 |
| ▸ | CTSS | P25774 | 6/20 | 0.53 |
| ▸ | CTSK | P43235 | 5/20 | 0.53 |
| ▸ | PPARD | Q03181 | 2/20 | 0.52 |
| ▸ | CTSL | P07711 | 1/20 | 0.52 |
| ▸ | CTSB | P07858 | 1/20 | 0.52 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.51 |
| ▸ | ITGA4 | P13612 | 1/20 | 0.51 |
| ▸ | ITGB7 | P26010 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16993952 | 1.00 | ITGB3 (0.65) | ITGB3ITGA2BACEPTPN1PPARA | |
| SCHEMBL8669351 | 1.00 | ITGB3 (0.65) | ITGB3ITGA2BACEPTPN1PPARA | |
| SCHEMBL13654528 | 0.90 | ITGB3 (0.62) | ITGB3ITGA2BACEPTPN1PPARA | |
| SCHEMBL16909032 | 0.90 | ITGB3 (0.65) | ITGB3ITGA2BACEPTPN1PPARA | |
| SCHEMBL14343235 | 0.90 | ITGB3 (0.65) | ITGB3ITGA2BACEPTPN1PPARA | |
| SCHEMBL1087185 | 0.90 | ITGB3 (0.65) | ITGB3ITGA2BACEPTPN1PPARA | |
| SCHEMBL5123922 | 0.89 | ITGB3 (0.52) | ITGB3ITGA2BACEPTPN1PPARA | |
| SCHEMBL1972111 | 0.89 | KLK5 (0.54) | ITGB3ITGA2BACEPPARAPPARG | |
| SCHEMBL5123928 | 0.89 | ITGB3 (0.52) | ITGB3ITGA2BACEPTPN1PPARA | |
| SCHEMBL1311509 | 0.87 | ITGB3 (0.67) | ITGB3ITGA2BACEPTPN1PPARA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5767158-A | FOR BLEACHING SKIN | SHISEIDO CO., LTD. (JP) | 1998-06-16 | — | — | US | claimed |
| US-7923004-B2 | useful in the production of a library of pyrazole derivatives for biological screening; Hepatitis C virus (HCV); ease of crystallization, yield, stability, solubility, hygroscopicity and flowability of the resulting bulk drug | XTL BIOPHARMACEUTICALS LTD. (IL) | 2011-04-12 | — | — | US | disclosed |
| US-7923004-B2 | useful in the production of a library of pyrazole derivatives for biological screening; Hepatitis C virus (HCV); ease of crystallization, yield, stability, solubility, hygroscopicity and flowability of the resulting bulk drug | XTL BIOPHARMACEUTICALS LTD. (IL) | 2011-04-12 | — | — | US | disclosed |
| US-7731949-B2 | — | — | 2010-06-08 | — | — | US | disclosed |
| US-7731949-B2 | — | — | 2010-06-08 | — | — | US | disclosed |
| US-20090041723-A1 | Compounds and methods for treatment of HCV | XTL BIOPHARMACEUTICALS LTD. (IL) | 2009-02-12 | — | — | US | disclosed |
| US-20090041723-A1 | Compounds and methods for treatment of HCV | XTL BIOPHARMACEUTICALS LTD. (IL) | 2009-02-12 | — | — | US | disclosed |
| US-7439258-B2 | Viral polymerase inhibitors | BOEHRINGER INGELHEIM (CANADA) LTD (CA) | 2008-10-21 | — | — | US | disclosed |
| US-7439258-B2 | Viral polymerase inhibitors | BOEHRINGER INGELHEIM (CANADA) LTD (CA) | 2008-10-21 | — | — | US | disclosed |
| US-5767158-A | FOR BLEACHING SKIN | SHISEIDO CO., LTD. (JP) | 1998-06-16 | — | — | US | disclosed |
| EP-0728469-A2 | An endermic liniment | SHISEIDO COMPANY LIMITED (JP) | 1996-08-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090041723-A1 | Compounds and methods for treatment of HCV | HAVCR2, EIF2AK2, MAVS | ITGB3 2071/4885ITGA2B 3715/4885ACE 241/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.